Revenue ($USD): $15,113,000,000
R&D spend: $605,000,000.00
Employees: 60,000
Fiscal year end: 12/31/22
CEO: José Almeida
In January, Baxterannounced plansto spin its renal care and acute therapies units into an independent, publicly traded company. Baxter expects the new, independent, publicly-traded company —called Vantive— to launch by July 2024.
Meanwhile,there is uncertain timingaround the sale of Baxter’s biopharma solutions (BPS) business. Baxter recently said it plans for the BPS sale to complete toward the end of the third quarter.
Said Baxter CEO José (Joe) Almeida: “These initiatives are focused on enhancing strategic clarity, increasing market responsiveness and accelerating innovation, in an effort to drive greater value for our stakeholders.”–CN